Genetic engineering to cure HIV
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV
This study is exploring a new way to potentially cure HIV by using special immune cells and antibodies to help the body fight the virus better, and it's designed for people living with HIV who are looking for improved treatment options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10833562 on NIH RePORTER |
What this research studies
This research investigates the potential to cure HIV-1 by combining gene-engineered cellular therapies, such as chimeric antigen receptor (CAR) T cells, with humoral therapies using broadly neutralizing antibodies (bNAbs). The approach aims to enhance the immune response against HIV-1 infected cells and improve the effectiveness of treatment. By utilizing hematopoietic stem/progenitor cells (HSPC) to deliver these engineered immune cells, the researchers hope to achieve better therapeutic outcomes. The study builds on previous successes in immunotherapy for cancer and aims to translate these findings to HIV treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV-1 who are seeking innovative treatment options.
Not a fit: Patients who are not infected with HIV-1 or those who have advanced stages of HIV-related complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a functional cure for HIV-1, significantly improving the lives of those affected by the virus.
How similar studies have performed: Previous research has shown promise in using similar gene-engineered therapies for cancer treatment, indicating potential for success in HIV treatment as well.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Kitchen, Scott G — University of California Los Angeles
- Study coordinator: Kitchen, Scott G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.